Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.

作者: Jacob J. Lokich , Henry Sonneborn , Norwood R. Anderson , Murray M. Bern , Frank V. Coco

DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2347::AID-CNCR8>3.0.CO;2-8

关键词:

摘要: BACKGROUND Paclitaxel (T), etoposide (E), and cisplatin (P) are each active in gastric carcinoma, either as single agents or part of a multidrug regimen. To the authors' knowledge, combination these three treatment patients with esophageal gastroesophageal carcinoma has not been previously studied. METHODS Previously untreated locally advanced stomach, esophagus, (GE) junction received at least 2 cycles TPE administered twice weekly for 3 weeks, cycle repeated every 28 days. Drug doses, over hours on Monday Thursday Tuesday Friday, consisted T 50 mg/m2/dose, P 15 E 40 mg/m2/dose. For local disease only, subsequent therapy radiation without surgical resection. RESULTS Twenty-five (10) GE (15) were treated. Eighteen had 7 liver metastases presentation. Hematologic toxicity, namely, Grade anemia neutropenia, was experienced by all patients. The median number 4 (range, 2–6). Three evaluable response. All 22 responded; complete responders 19 partial responders. Eleven (6) (5) concomitant 5-fluorouracil, 8 subsequently underwent resection. no tumor surgery, minimal microscopic primary site, lymph node involvement. Twenty-three alive, whom 14 evidence disease. Two metastatic presentation died 9 29 months, respectively. survival 12.5 months 6 to 30+ months). CONCLUSIONS Multifractionated chemotherapy is highly regimen carcinoma. It could be evaluated Phase III trials against other regimens this introduction 5-fluorouracil also an interesting direction explore because its role Cancer 1999;85:2347–51. © 1999 American Society.

参考文章(12)
A Webb, D Cunningham, J H Scarffe, P Harper, A Norman, J K Joffe, M Hughes, J Mansi, M Findlay, A Hill, J Oates, M Nicolson, T Hickish, M O'Brien, T Iveson, M Watson, C Underhill, A Wardley, M Meehan, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology. ,vol. 15, pp. 261- 267 ,(1997) , 10.1200/JCO.1997.15.1.261
P Preusser, H Wilke, W Achterrath, U Fink, L Lenaz, A Heinicke, J Meyer, H J Meyer, H Buente, Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1310- 1317 ,(1989) , 10.1200/JCO.1989.7.9.1310
A Lerner, R Gonin, G D Steele, R J Mayer, Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. Journal of Clinical Oncology. ,vol. 10, pp. 536- 540 ,(1992) , 10.1200/JCO.1992.10.4.536
J Lokich, N Anderson, C Moore, M Bern, F Coco, H Sonneborn, E Dow, D Strong, Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas European Journal of Cancer. ,vol. 34, pp. 664- 667 ,(1998) , 10.1016/S0959-8049(97)10108-3
A. Webb, D. Cunningham, F. Cotter, P. Ross, J. Walters, I. Judson, F. Raynaud, P. Clarke, Z.E. Dziewanowska, First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial European Journal of Cancer. ,vol. 33, ,(1997) , 10.1016/S0959-8049(97)86090-X
J. A. Ajani, D. H. Ilson, K. Daugherty, R. Pazdur, P. M. Lynch, D. P Kelsen, Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus Journal of the National Cancer Institute. ,vol. 86, pp. 1086- 1091 ,(1994) , 10.1093/JNCI/86.14.1086
M. Findlay, D. Cunningham, A. Norman, J. Mansi, M. Nicolson, T. Hickish, V. Nicolson, A. Nash, N. Sacks, H. Ford, R. Carter, A. Hill, A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF) Annals of Oncology. ,vol. 5, pp. 609- 616 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058932
H Safran, T P King, H Choy, P J Hesketh, B Wolf, E Altenhein, W Sikov, A Rosmarin, W Akerley, K Radie-Keane, G Cicchetti, F Lopez, K Bland, H J Wanebo, Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. Journal of Clinical Oncology. ,vol. 15, pp. 901- 907 ,(1997) , 10.1200/JCO.1997.15.3.901
C S Fuchs, Chemotherapy for advanced gastric cancer: where do we stand? Journal of Clinical Oncology. ,vol. 15, pp. 3299- 3300 ,(1997) , 10.1200/JCO.1997.15.11.3299
S Cascinu, R Labianca, P Alessandroni, M Marcellini, R R Silva, G Pancera, E Testa, G Martignoni, S Barni, L Frontini, A Zaniboni, G Luporini, R Cellerino, G Catalano, Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. Journal of Clinical Oncology. ,vol. 15, pp. 3313- 3319 ,(1997) , 10.1200/JCO.1997.15.11.3313